The aim of MicrobLiver is to obtain understanding of the interaction between the host and gut microbiome in humans and the role of the gut-liver axis in early stages of alcoholic and non-alcoholic fatty liver disease.

This understanding will be utilized to build models that describe the gut microbiome–portal vein–liver axis and to identify biomarkers for predicting, preventing and treating metabolic liver diseases. Based on clinical observational and interventional study, omics-based techniques will provide novel insight into the role of gut microbiota dysbiosis in the pathogenesis of NAFLD, NASH and alcoholic liver disease.


The main aim of the study is to identify metabolomics signatures in obese young individuals and obesity-related metabolic alterations, such as inflammation or oxidative stress. The study involves plasma samples from 1425 children, lipidomics will be employed to identify lipid signatures associated with obesity and its-related metabolic alterations.


MicrobLiver is a consortium of leading basic scientists and clinical researchers. The principal investigator, Torben Hansen, is professor at Novo Nordisk Foundation Center for Basic Metabolic Research. Other significant partners of the consortium include Matthias Mann, Jelle Matthijnssens, Peer Bork, Aleksander Krag, Flemming Bendtsen, Jonel Trebicka and Allan Vaag.